MOTS-c and NAD+: Where Mitochondrial Peptides Meet Energy

Sirtuins and Peptide Longevity

16 amino acids

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK through inhibition of the folate cycle, linking mitochondrial signaling to NAD+ metabolism.

Zheng et al., Frontiers in Endocrinology, 2023

Zheng et al., Frontiers in Endocrinology, 2023

View as image

The discovery that mitochondria produce their own signaling peptides rewrote a basic assumption in biology. For decades, mitochondria were treated as passive energy factories. The identification of MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) in 2015 revealed that these organelles actively communicate with the nucleus through peptide signals, forming a retrograde signaling axis that regulates metabolism, stress responses, and aging. MOTS-c connects directly to NAD+ metabolism through its primary mechanism of action: inhibiting the folate cycle and its linked de novo purine biosynthesis pathway, which leads to AMPK activation and downstream metabolic reprogramming.^[1] This positions MOTS-c at the intersection of two of the most active areas in longevity research: mitochondrial-derived peptides and the NAD+/sirtuin pathway.

How MOTS-c Connects to NAD+ Metabolism

MOTS-c's relationship to NAD+ is not direct binding or enzymatic activity. Instead, MOTS-c alters the metabolic fluxes that determine NAD+ availability.

The folate cycle (one-carbon metabolism) feeds into de novo purine biosynthesis, which consumes substrates shared with the NAD+ salvage and biosynthesis pathways. When MOTS-c inhibits the folate cycle, precursor metabolites accumulate, including intermediates in NAD+ metabolism and glycolysis. This metabolic disruption triggers AMPK (AMP-activated protein kinase) activation, the cell's master energy sensor.^[1]

AMPK activation has cascading effects on NAD+ biology:

• It increases NAD+ levels by upregulating nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway
• It activates SIRT1 and SIRT3 (NAD+-dependent deacetylases) through the increased NAD+/NADH ratio
• It promotes mitochondrial biogenesis through PGC-1alpha, creating a positive feedback loop: more mitochondria produce more MOTS-c, which activates more AMPK

This molecular cascade means MOTS-c functions as a bridge between mitochondrial health and the NAD+/sirtuin axis. When mitochondria are stressed or dysfunctional, MOTS-c production may decline, reducing AMPK activation, lowering NAD+ levels, and dampening sirtuin activity. The result is a downward spiral linking mitochondrial dysfunction to the metabolic decline of aging.

From Mitochondria to Nucleus: The Translocation Event

One of MOTS-c's most unusual properties is its ability to move from mitochondria to the cell nucleus during metabolic stress. This retrograde signaling breaks the traditional view that mitochondria receive instructions from nuclear DNA without sending peptide signals back.

Zheng and colleagues documented that under conditions of metabolic stress, MOTS-c protein translocates to the nucleus and directly influences the expression of nuclear genes involved in glucose metabolism, antioxidant defense, and proteostasis.^[1] This nuclear translocation is critical because it means MOTS-c is not merely a circulating peptide with receptor-mediated effects. It acts as an intracellular signal that coordinates mitochondrial and nuclear gene expression in response to metabolic challenges.

The trigger for translocation appears to be cellular energy status. When AMPK is activated (indicating low energy), MOTS-c moves to the nucleus. This creates a sensor-and-response system: mitochondrial stress produces MOTS-c, which enters the nucleus to adjust gene expression, which in turn helps restore metabolic balance.

MOTS-c as an Exercise Mimetic

Reynolds and colleagues published a landmark study in Nature Communications in 2021 demonstrating that MOTS-c functions as an exercise-induced regulator of physical decline.^[2]

Key findings:

• Exercise induces endogenous MOTS-c expression in both skeletal muscle and circulation in humans
• Exogenous MOTS-c treatment enhanced physical performance in young (2-month), middle-aged (12-month), and old (22-month) mice
• Late-life initiated MOTS-c treatment (starting at 23.5 months, roughly equivalent to age 70 in humans) given 3 times per week increased physical capacity and healthspan
• MOTS-c regulated nuclear genes related to metabolism and proteostasis, and modified skeletal muscle metabolism

The exercise connection is mechanistically coherent: exercise activates AMPK, increases NAD+ levels, promotes mitochondrial biogenesis, and stimulates MOTS-c production. MOTS-c may represent one of the molecular mediators through which exercise produces its metabolic benefits. The fact that exogenous MOTS-c can partially replicate exercise effects in mice (improved physical capacity, better metabolic homeostasis) supports its characterization as an exercise mimetic, though the magnitude of benefit is smaller than actual exercise.

Genetic Evidence: The K14Q Polymorphism

Some of the strongest human evidence for MOTS-c's functional importance comes from a natural experiment: a mitochondrial DNA polymorphism that produces an altered version of the peptide.

Zempo and colleagues analyzed 27,527 individuals across three cohorts (J-MICC, MEC, and TMM) and identified an Asian-specific mtDNA variant (m.1382A>C) that replaces lysine with glutamine at position 14 of the MOTS-c sequence (K14Q).^[3]

The findings were striking:

• Men with the C-allele had higher prevalence of type 2 diabetes
• The diabetes risk was amplified in men with low physical activity, demonstrating a kinesio-genomic interaction: exercise could partially compensate for the less functional MOTS-c variant
• In mice, wild-type MOTS-c reduced weight and improved glucose tolerance when injected into high-fat-fed males, but K14Q-MOTS-c (the variant form) did not
• The K14Q substitution reduced MOTS-c's insulin-sensitizing activity in cell culture
• Females were unaffected in both human and mouse data

This sex-specific effect suggests MOTS-c's metabolic role may interact with sex hormones or sex-specific metabolic pathways. The exercise interaction is particularly compelling: it shows that physical activity and MOTS-c converge on the same metabolic pathway, and that sufficient exercise can overcome a genetic handicap in MOTS-c function.

MOTS-c and How It Activates AMPK

The AMPK activation produced by MOTS-c has direct consequences for insulin sensitivity. AMPK promotes GLUT4 translocation to the cell surface in skeletal muscle, enabling glucose uptake independently of insulin signaling. This is the same mechanism through which exercise improves glucose handling in insulin-resistant individuals.

In preclinical models, MOTS-c treatment:

• Reduced fasting blood glucose in diabetic rodents
• Improved glucose tolerance and insulin sensitivity
• Protected pancreatic beta cells from injury
• Enhanced glucose uptake in skeletal muscle cells

Circulating MOTS-c levels are lower in patients with type 2 diabetes compared to healthy controls, suggesting that endogenous MOTS-c production declines as metabolic disease progresses. Whether this decline is a cause or consequence of metabolic dysfunction is not established, but the preclinical evidence showing that exogenous MOTS-c corrects metabolic abnormalities supports a causal role.

The Age-Related Decline

MOTS-c levels in plasma decrease with age. This decline parallels the age-related reduction in NAD+ levels, sirtuin activity, AMPK responsiveness, and mitochondrial function. Whether MOTS-c decline drives these other changes, results from them, or represents a parallel manifestation of mitochondrial aging is an open question.

What is clear is that the decline is measurable and correlates with functional outcomes. The Reynolds 2021 study showed that even late-life MOTS-c supplementation (analogous to starting treatment at age 70) could improve physical capacity in mice, suggesting that the age-related decline is at least partially reversible through exogenous replacement.^[2]

The convergence with other longevity pathways is notable. NAD+ declines with age. Sirtuin activity declines with age. AMPK responsiveness declines with age. MOTS-c declines with age. These parallel declines suggest a coordinated deterioration of the metabolic defense network, and MOTS-c sits at a node connecting them all.

MOTS-c in Disease Models

Beyond its role in normal metabolic regulation, MOTS-c has shown therapeutic effects across multiple disease models that share mitochondrial dysfunction as a common thread.

Type 2 diabetes. MOTS-c treatment reduced fasting blood glucose, improved glucose tolerance, and enhanced insulin sensitivity in diabetic rodent models. Circulating MOTS-c levels are lower in patients with type 2 diabetes compared to healthy controls, establishing a correlation between endogenous MOTS-c depletion and metabolic disease.^[1]

Gestational diabetes. In a mouse model of gestational diabetes induced by high-fat diet and streptozotocin, daily MOTS-c administration during pregnancy alleviated hyperglycemia, improved insulin sensitivity, reduced birth weight, and decreased offspring mortality. MOTS-c also protected pancreatic beta cells from injury, addressing both the metabolic and reproductive consequences of gestational diabetes.

Skeletal muscle dysfunction. MOTS-c regulates skeletal muscle metabolism directly, enhancing glucose uptake through AMPK-mediated GLUT4 translocation. Dieli-Conwright and colleagues demonstrated in 2021 that aerobic and resistance exercise both increase circulating MOTS-c in humans, with the increase correlating to improvements in metabolic markers.^[4]

Cardiovascular disease. Preclinical evidence suggests MOTS-c has cardioprotective effects through AMPK activation, reduction of oxidative stress, and anti-inflammatory signaling. The overlap with NAD+/sirtuin-mediated cardioprotection suggests these pathways may work synergistically.

Inflammation. MOTS-c reduces inflammatory markers in multiple tissue types, consistent with AMPK's known anti-inflammatory effects. The anti-inflammatory activity may contribute to MOTS-c's benefits in metabolic disease, where chronic low-grade inflammation drives insulin resistance and tissue damage.

The common thread across these disease models is mitochondrial dysfunction. In each condition, mitochondrial energy production is impaired, MOTS-c levels are reduced, and exogenous MOTS-c supplementation partially corrects the metabolic defect. This supports the hypothesis that MOTS-c acts as a mitochondrial health signal: when mitochondria function well, they produce adequate MOTS-c to maintain metabolic homeostasis. When they fail, the loss of MOTS-c accelerates metabolic decline.

Current Limitations

MOTS-c research remains almost entirely preclinical. No human clinical trials of exogenous MOTS-c have been reported. The human data is limited to:

• Observational studies showing MOTS-c levels are lower in diabetes and decline with age
• Genetic epidemiology (the K14Q polymorphism study)
• Exercise physiology studies showing MOTS-c increases with exercise

Several practical barriers exist for clinical translation:

• Manufacturing a 16-amino-acid peptide encoded by mitochondrial DNA is technically feasible but has not been scaled for pharmaceutical production
• The optimal dose, route, and frequency of administration are unknown
• Whether exogenous MOTS-c replicates the nuclear translocation observed with endogenous MOTS-c is not confirmed
• Long-term safety of chronic AMPK activation through MOTS-c is uncharacterized
• The sex-specific effects observed in the K14Q data suggest that MOTS-c-based interventions may need to account for sex differences

The NAD+ and peptide longevity pathway intersection is an area where MOTS-c may prove particularly important. NAD+ precursors like NMN and NR are widely marketed as anti-aging supplements, but they target NAD+ from the supply side. MOTS-c targets NAD+ from the demand and regulation side, through AMPK-mediated upregulation of NAMPT. Whether combining NAD+ precursors with MOTS-c would produce additive or synergistic effects on sirtuin activation and mitochondrial function is an untested but biologically plausible hypothesis.

Connections to other longevity peptides like epithalon (which targets telomerase) and Khavinson bioregulators are speculative at this stage. Each targets a different aspect of aging biology, and no studies have examined interactions between mitochondrial-derived peptides and other anti-aging peptide classes.

The Bottom Line

MOTS-c connects mitochondrial biology to NAD+ metabolism through a specific mechanism: inhibition of the folate cycle leads to AMPK activation, which increases NAD+ levels and activates sirtuins. This positions MOTS-c at a central node linking mitochondrial health, cellular energy sensing, and the longevity-associated NAD+/sirtuin pathway. The strongest evidence comes from the Nature Communications exercise study (late-life treatment improved healthspan in mice) and the 27,527-person genetic study (a loss-of-function MOTS-c variant increases diabetes risk in sedentary men). All therapeutic potential remains preclinical. No human trials of exogenous MOTS-c exist, and the translation from fascinating biology to viable therapy has not yet occurred.

Frequently Asked Questions

What is MOTS-c and what does it do?

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA (specifically the 12S rRNA region). It activates the cell's energy sensor AMPK by inhibiting the folate cycle. This leads to increased NAD+ levels, improved insulin sensitivity, and enhanced glucose metabolism. During metabolic stress, MOTS-c travels from mitochondria to the cell nucleus to regulate gene expression. Its levels decline with age.

How does MOTS-c affect NAD+ levels?

MOTS-c increases NAD+ indirectly. By inhibiting the folate cycle and activating AMPK, it upregulates NAMPT (the enzyme that produces NAD+ through the salvage pathway) and shifts the NAD+/NADH ratio in favor of NAD+. Higher NAD+ activates sirtuins (SIRT1, SIRT3), which regulate mitochondrial function and cellular repair.

Does exercise increase MOTS-c?

Yes. In humans, exercise increases MOTS-c levels in both skeletal muscle and blood. A 2021 Nature Communications study showed that MOTS-c is an exercise-induced mitochondrial signal. In mice, exogenous MOTS-c partially replicated exercise benefits, including improved physical capacity even when started late in life (equivalent to age 70 in humans).

Can you take MOTS-c as a supplement?

MOTS-c is not available as an approved drug or regulated supplement. All evidence for its therapeutic potential comes from animal studies and human observational data. No human clinical trials of exogenous MOTS-c have been conducted. Manufacturing, dosing, and long-term safety remain unresolved.

Why do MOTS-c levels decline with age?

The exact cause is unknown, but it likely reflects declining mitochondrial function. As mitochondria accumulate damage and lose efficiency with age, their production of MOTS-c decreases. This creates a negative feedback loop: less MOTS-c means less AMPK activation, lower NAD+ levels, reduced sirtuin activity, and further mitochondrial decline.

Does a MOTS-c gene variant increase diabetes risk?

Yes. An Asian-specific mitochondrial DNA variant (m.1382A>C) produces a K14Q amino acid change in MOTS-c that reduces its insulin-sensitizing ability. In a study of 27,527 people, men with this variant had higher type 2 diabetes prevalence, especially if they were physically inactive. Exercise appeared to compensate for the reduced MOTS-c function.